论文部分内容阅读
本文为了探讨雄激素对再生障碍性贫血(再障)患者抗胸腺细胞球蛋白(ATG)疗效的影响和小剂量ATG治疗再障的疗效。作者前瞻随机性用ATG100mg/kg,同时加用或不加Ⅰ-甲雄烯醇酮(Methenolone)3mg/kg治疗30例再障(其中18例重型再障),15例有效。接受ATG+雄激素治疗的15例中11例有效(73%),其中8例完全缓解(CR),3例部分缓解(PR);单用ATG治疗15例中仅4例有效(31%),其中2例CR,2例PR,两组有效率相比有显著性差异(P=0.01)。本文病例总的生存率为64%,ATG+雄激素组生存率是87%,单用ATG组
This article was designed to investigate the effects of androgens on the anti-thymocyte globulin (ATG) response in patients with aplastic anemia (aplastic anemia) and the effects of low-dose ATG on aplastic anemia. The prospective randomized trial of ATG 100 mg / kg with or without Methenolone 3 mg / kg in 30 cases of aplasia (including 18 cases of aplastic Anemia) was effective in 15 cases. Eleven of the 15 patients (73%) treated with ATG + androgen therapy were effective (CR, 8) and 3 (PR). Only 4 of 15 (31%) treated with ATG alone were effective Two cases of CR, two cases of PR, the effective rate of the two groups was significantly different (P = 0.01). The overall survival rate of this case was 64%, the ATG + androgen group survival rate was 87%, with ATG alone